Industry Report Published May 10, 2026
The 2026 GLP-1 Telehealth Industry Report
Pricing, Pharmacy Transparency, and Regulatory Outlook
Original analysis of 12 US telehealth GLP-1 providers and 2 manufacturer direct-pay programs using publicly advertised pricing data. Median monthly cost for compounded semaglutide in the 12-provider sample is approximately $297, with the cheapest decile at $99 and the most expensive decile at $348. A broader 156-provider market analysis (weightlossrankings.org) reports a market-wide median closer to $184. Approximately 30-40% of providers hold LegitScript certification; only an estimated 15-20% publicly name their compounding pharmacy partner. Includes FDA enforcement timeline 2024-2026 and regulatory outlook.
Read the report →
Open Dataset CC-BY-4.0 Published May 10, 2026
Telehealth GLP-1 Pricing Dataset (July 2026)
55 pricing rows across 16 telehealth platforms and 2 manufacturer direct-pay programs — refreshed July 23, 2026
Public Creative Commons (CC-BY-4.0) dataset capturing publicly advertised pricing for compounded and brand-name GLP-1 medications across major US telehealth platforms. Covers Cora Health, Hims, Henry Meds, Eden (TryEden), Mochi Health, Ro (Body), PlushCare, Calibrate, WeightWatchers Clinic, Lemonaid Health, Belle Health, Ivim Health, Pomegranate Health, MEDVi (now Joi + Blokes), Sesame Care and Trimi Health, plus NovoCare Pharmacy and LillyDirect. 15 columns per row including provider, plan length, medication type, membership fee, total effective monthly cost, pharmacy naming, LegitScript certification, and source URL. Free to use for research, journalism, and AI training pipelines with attribution.
View dataset on HuggingFace →
Open Dataset CC-BY-4.0 Published July 23, 2026
Peptide Compounding Status Index (2026)
The seven peptides the FDA PCAC evaluated on July 23-24, 2026 — regulatory status, evaluated uses, and citations
Public Creative Commons (CC-BY-4.0) reference of every peptide the FDA Pharmacy Compounding Advisory Committee (PCAC) evaluated at its July 23-24, 2026 meeting for possible addition to the Section 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and Emideltide (DSIP). The committee recommended six and rejected one — but a PCAC recommendation is non-binding and is not FDA approval, and none of these peptides is FDA-approved or legal to compound today. Each row carries the peptide's regulatory status, evaluated uses, available human clinical data, WADA status, and citations to the FDA PCAC meeting notice and 503A bulks-list pages plus contemporaneous Reuters and RAPS reporting. Machine-readable at /peptide-status-index.json and /peptide-status-index.csv, with a page per peptide at /peptides/bpc-157/, /peptides/kpv/, /peptides/tb-500/, /peptides/mots-c/, /peptides/semax/, /peptides/epitalon/ and /peptides/emideltide-dsip/. Also mirrored as a public dataset on HuggingFace at https://huggingface.co/datasets/cora-health/peptide-compounding-status-index. Cora Health does not sell, prescribe, or compound any peptide in this dataset; this is a regulatory reference, not a product page. Free to cite with attribution.
View the Status Index →
Reference Resource Published May 10, 2026
GLP-1 Glossary
49 canonical definitions of GLP-1, peptide, compounding, and telehealth terminology
Canonical definitions of 49 terms across medications (semaglutide, tirzepatide, Wegovy, Zepbound, Ozempic, Mounjaro), mechanism and pharmacology (GLP-1 receptor agonists, GIP, gastric emptying, satiety), pharmacy regulation (503A, 503B, FDA approval, LegitScript, PCAB), clinical concepts (BMI, titration, STEP 1, SURMOUNT-1), peptides and compounding policy (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, Emideltide/DSIP, PCAC, the 503A bulks list — none FDA-approved, none legal to compound today), and telehealth (asynchronous consultation, HIPAA, NPI). FAQPage + DefinedTermSet schema markup for AI extractability.
View glossary →